Similar Prognosis of Patients with Bone-only Metastatic Breast Cancer and Visceral Metastasis

Background: Bone-only metastatic breast cancer is believed to be non-life-threatening, and mild therapy frequently selected avoid adverse events of drug therapy. However, the prognoses such patients are not well studied. Methods: Patients who received therapies for between 2004 2016 at our institution were divided into “Bone-only metastasis”, “non-visceral”, “visceral” groups based on mode first metastasis, efficacy first-line survival these compared. Results: There 131 eligible patients, bone-only non-visceral, visceral included 26, 25, 80 respectively. The median time (MST) overall (OS) in each group was 35.1, 34.9, 37.4 months, respectively (p=0.71). clinical benefit rates 66.7%, 45%, 69.3%, respectively, MST treatment failure (TTF) 6.3, 5.5, 5.8 showing that did significantly differ among groups. In metastasis group, with <5 metastases tended have a good prognosis, those low nuclear grade long duration had better prognosis than others. Conclusion: similar response other modes prognosis.